Where are the phase IIb results for Bimatoprost?

[It's2014ComeOnAlready]

And reread your posts - you're not connecting dots, you're making dots up and then speculating about fictitious info. There is absolutely nothing to back up most of what you said.

Ugh, then don't read my posts. I don't make up dots, and I never have. I don't have the time to re-reference what I post. You're just uninformed. This is why I didn't want to post about this, because I knew somebody would come out of the blue and say "ur making this stuff up."

Bottom line: I don't give a crap what you think. I don't pull stuff from thin air. If you're curious, from now on, do your own damn homework.

BTW you've speculated a ton with how important Seti is to Allergan, as well as pretty much everything about their double-chin drug.

[Hemo]

(and I'm not trying to be negative, just a realist. The fact of the matter is that none of this means anything until a product is released).

[Hemo]

So you think that Set was "just a bonus" and doesn't fit with anything they have? lol The people who run these companies are extremely calculating.

To think that they bought a company for $2B and all they wanted a was a drug that is matched by diet and exercise.

Also that Allergan rep was their CEO who said that Set will "Drive additional long term growth." That's quite an endorsement.

My ideas aren't grandiose. I've done a lot of research, and I connect the dots the best I can. Sorry you disagree, maybe you should do a little more homework.

Yes, I think they likely saw some value in Seti, but I think their commitment will come down to how much more they have to invest. If it's effective and won't require another 10 years to develop, then sure, I bet they're happy.

And to shrug off the double chin treatment because it's something that has the same effect as diet and exercise is incredibly naive. How many women have you heard say they would like to lose a couple pounds? How many do you think would prefer to stop by a doctor's office for an injection rather than spend months at the gym while eating well? The fact of the matter is that people are lazy, and even if it's just for double chins, they're making it incredibly easy to get rid of, which will attract many many people that a.) don't exercise routinely and b.) don't want surgery. TBH, I'd bet they're more interested in expanding the research for this treatment for other parts of the body than they are in Seti.

I'm not saying Seti will get dropped (hell, it could be incredibly effective), but I doubt Allergan would have given Kythera the time of day without the chin treatment. And reread your posts - you're not connecting dots, you're making dots up and then speculating about fictitious info. There is absolutely nothing to back up most of what you said.

[Trouse5858]

The fact that they care more about a freaking double chin treatment (AKA don't be a fat slob. Cured!) as opposed to hairloss makes me want to light myself on fire and jump out of a building.

[It's2014ComeOnAlready]

I really think you're overemphasizing the Kythera acquisition. Lets face it, Allergan wanted the double chin treatment and anything else is a bonus. There's no reason for an Allergan rep to talk poorly about set until they decide what they truly want to do with it, of course he's gonna say he's excited. You and nameless keep coming up with these grandiose ideas of what's going on behind the scenes for bim and SM when we really have no clue, and won't until something is released.

So you think that Set was "just a bonus" and doesn't fit with anything they have? lol The people who run these companies are extremely calculating.

To think that they bought a company for $2B and all they wanted a was a drug that is matched by diet and exercise.

Also that Allergan rep was their CEO who said that Set will "Drive additional long term growth." That's quite an endorsement.

My ideas aren't grandiose. I've done a lot of research, and I connect the dots the best I can. Sorry you disagree, maybe you should do a little more homework.

[Hemo]

lol ok fine. There are just some dudes on here who test my patience with their endless negativity, and being so contrary just for the sake of it. It cannot skip phase 3.

I've done a lot of digging - reading articles, watching interviews etc. It seems to me that a very likely scenario is that they've continued on with trials. However, the trial hasn't been posted to clinicaltrials.gov with very good reason.

Firstly, this drug already exists in the market, and according to former Allergan CEO David Pyott, many people were trying to get their hands on latisse before it got to market. In this case, it would be worse because other companies can make the drug, and if you wanted, you could buy pure bimatoprost powder off a website like alibaba.com and make it yourself. This would hurt their profits and their customers. The drug has not passed trials yet, and the FDA wouldn't want an outrageous situation where a popular hair loss treatment would get in the hands of the public in a unsafe and unregulated fashion, because this would undoubtedly happen if word got out.

Secondly, they set up their phase 2 trials with enough participants so that if they saw positive results, they could immediately jump into a phase 3. Therefore, posting to clinicaltrials.gov as a recruitment tool wouldn't be necessary.

So, I think they could have quietly progressed, and in accordance with the FDA, have omitted their trial to be posted on clinicaltrials.gov, for the reasons I have posted. It's unusual, complex, but I think it makes more sense then them slowing down the program by a year, if it was successful. There's no reason to do that.

I also think the acquisition of Kythera and Setipiprant is good reason to believe bimatoprost worked. With that move, it proves they want to dominate the medical aesthetics market. Not only that, but they are mutually reliant on prostaglandin science, which is why they are as positive about Setipiprant as they are. About 10% of men do something about their hair loss. With a side effect-free drug like setipiprant, and a drug that will regrow anywhere on the scalp, that number would jump to near 100%. Which means $$$$$$$$$$$$. No man wants to be bald.

I really think you're overemphasizing the Kythera acquisition. Lets face it, Allergan wanted the double chin treatment and anything else is a bonus. There's no reason for an Allergan rep to talk poorly about set until they decide what they truly want to do with it, of course he's gonna say he's excited. You and nameless keep coming up with these grandiose ideas of what's going on behind the scenes for bim and SM when we really have no clue, and won't until something is released.

[It's2014ComeOnAlready]

That's a lot of confidence... I'd love for you to be right!

Can you imagine the stampede of people trying to get bimatoprost the black market route, or the number of labs that would concoct and sell it themselves if word got out?

[Slam1523]

lol ok fine. There are just some dudes on here who test my patience with their endless negativity, and being so contrary just for the sake of it. It cannot skip phase 3.

I've done a lot of digging - reading articles, watching interviews etc. It seems to me that a very likely scenario is that they've continued on with trials. However, the trial hasn't been posted to clinicaltrials.gov with very good reason.

Firstly, this drug already exists in the market, and according to former Allergan CEO David Pyott, many people were trying to get their hands on latisse before it got to market. In this case, it would be worse because other companies can make the drug, and if you wanted, you could buy pure bimatoprost powder off a website like alibaba.com and make it yourself. This would hurt their profits and their customers. The drug has not passed trials yet, and the FDA wouldn't want an outrageous situation where a popular hair loss treatment would get in the hands of the public in a unsafe and unregulated fashion, because this would undoubtedly happen if word got out.

Secondly, they set up their phase 2 trials with enough participants so that if they saw positive results, they could immediately jump into a phase 3. Therefore, posting to clinicaltrials.gov as a recruitment tool wouldn't be necessary.

So, I think they could have quietly progressed, and in accordance with the FDA, have omitted their trial to be posted on clinicaltrials.gov, for the reasons I have posted. It's unusual, complex, but I think it makes more sense then them slowing down the program by a year, if it was successful. There's no reason to do that.

I also think the acquisition of Kythera and Setipiprant is good reason to believe bimatoprost worked. With that move, it proves they want to dominate the medical aesthetics market. Not only that, but they are mutually reliant on prostaglandin science, which is why they are as positive about Setipiprant as they are. About 10% of men do something about their hair loss. With a side effect-free drug like setipiprant, and a drug that will regrow anywhere on the scalp, that number would jump to near 100%. Which means $$$$$$$$$$$$. No man wants to be bald.

That's a lot of confidence... I'd love for you to be right!

[It's2014ComeOnAlready]

I'd quite like to hear why you think it will be able to miss phase 3 . Like not to argue just because it's interesting! And to be fair I've only heard of Bim from my Grandad because his eyes are messed up haha! I understand that bim is currently used in eye drops ect and for lattisse but has there ever been drugs allowed to skip phase 3 for a different use kind of thing?

lol ok fine. There are just some dudes on here who test my patience with their endless negativity, and being so contrary just for the sake of it. It cannot skip phase 3.

I've done a lot of digging - reading articles, watching interviews etc. It seems to me that a very likely scenario is that they've continued on with trials. However, the trial hasn't been posted to clinicaltrials.gov with very good reason.

Firstly, this drug already exists in the market, and according to former Allergan CEO David Pyott, many people were trying to get their hands on latisse before it got to market. In this case, it would be worse because other companies can make the drug, and if you wanted, you could buy pure bimatoprost powder off a website like alibaba.com and make it yourself. This would hurt their profits and their customers. The drug has not passed trials yet, and the FDA wouldn't want an outrageous situation where a popular hair loss treatment would get in the hands of the public in a unsafe and unregulated fashion, because this would undoubtedly happen if word got out.

Secondly, they set up their phase 2 trials with enough participants so that if they saw positive results, they could immediately jump into a phase 3. Therefore, posting to clinicaltrials.gov as a recruitment tool wouldn't be necessary.

So, I think they could have quietly progressed, and in accordance with the FDA, have omitted their trial to be posted on clinicaltrials.gov, for the reasons I have posted. It's unusual, complex, but I think it makes more sense then them slowing down the program by a year, if it was successful. There's no reason to do that.

I also think the acquisition of Kythera and Setipiprant is good reason to believe bimatoprost worked. With that move, it proves they want to dominate the medical aesthetics market. Not only that, but they are mutually reliant on prostaglandin science, which is why they are as positive about Setipiprant as they are. About 10% of men do something about their hair loss. With a side effect-free drug like setipiprant, and a drug that will regrow anywhere on the scalp, that number would jump to near 100%. Which means $$$$$$$$$$$$. No man wants to be bald.

[JayM]

I'd quite like to hear why you think it will be able to miss phase 3 . Like not to argue just because it's interesting! And to be fair I've only heard of Bim from my Grandad because his eyes are messed up haha! I understand that bim is currently used in eye drops ect and for lattisse but has there ever been drugs allowed to skip phase 3 for a different use kind of thing?

[It's2014ComeOnAlready]

'2014' where did the poster 'bornthisway' post this news about the derm's office in contact with Allergan?

https://www.baldtruthtalk.com/threads/19498-Where-are-the-phase-IIb-results-for-Bimatoprost/page15

bottom of the page

[20legend]

'2014' where did the poster 'bornthisway' post this news about the derm's office in contact with Allergan?

[It's2014ComeOnAlready]

How can they release it without phase 3?

I'd mention what I believe is going on, but I don't feel like getting into a debate. Please see my other posts in this thread regarding phase 3.

If you don't think it's at all possible, I'm calling BS, because they'd be at a serious disadvantage by posting that they are in a phase 3 trial, while the drug is already in the market. There's also the issue of people wanting to get their hands on this drug before it reaches the market, and they had the same problem with latisse earlier on.

[JayM]

How can they release it without phase 3?

[It's2014ComeOnAlready]

It would be the happiest day of my life

That makes two of us